Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Industrial application

Retaining female talents

While the life sciences environment is adjusting to be able to foster female talents in the workplace, there is still a long way to go to achieve truly egalitarian work conditions. From the ‘motherhood penalty’ to unconscious bias, women can still be made to feel unwelcome in their daily work life. This is what motivated Veroniek Vermeulen to launch Silatha, a company with the goal of creating an environment where everyone can thrive.

The women of BioVox

STEM has had a long reputation of being a masculine environment, though recent efforts have made this field much more accessible to all genders. Our gender can influence both the external factors and internal methods affecting how we work.

Fraud in scientific institutes: a crack in the fabric of science

The pursuit of scientific knowledge is at the heart of human progress – it leads to ground-breaking discoveries that have transformed our understanding of the world and our place within it. However, this noble pursuit is not without its blemishes. Scientific fraud – the deliberate misrepresentation of data or results to deceive the scientific community – poses a serious threat to the integrity of the scientific enterprise in both academia and industry. So, what can we do about it?

Fund+ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk in potential 1-billion-euro deal

Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in RNA-based therapies that have the potential to prevent, repair and reverse diseases of the heart. The company’s approach targets distinctive non-coding RNAs to address the root causes of cardiac dysfunctions and achieve lasting patient impact.

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

  • Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from current and new leading global biotechnology investors
  • Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US

Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant

Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology

Bridging the immunity gap: improving animal welfare without antibiotics

Antibiotic resistance is a major concern for humans and animals. Increasing pressure to move away from antibiotics has created space for new solutions for disease management. Animab’s oral monoclonal antibody platform is a promising alternative, effectively guarding against infection during a vulnerable period in an animal’s development.

Looking forward: Azalea Vision’s smart lens is a game-changer for ocular disorders

In December 2023, Azalea Vision announced the first test of their smart contact lens on a real person. This demonstration showcased the first functional prototype of their smart lens, known as the ALMA lens, which was developed by the company to address ocular disorders characterized by the inability to effectively filter light.

V-Bio Ventures portfolio company Protealis secures EUR 22 million in oversubscribed B round funding to propel sustainable plant protein seed solutions

Protealis, a leading innovator in seed solutions for sustainable plant proteins based in Ghent, Belgium, proudly announced today the successful completion of its B-Round funding, raising a substantial EUR 22 million.

QbD Chair for Precision Oncology Research in Glioblastoma extended for three years

The QbD Chair supports the research of Professor Frederik De Smet on glioblastoma, an aggressive form of brain cancer. Behind the establishment of the Chair lies a personal story.

How the Chair of the Board can empower a first-time biotech CEO

Stepping into the role of a Chief Executive Officer (CEO) for the first time can be a daunting prospect. In the biotech industry, the journey is marked by a unique set of hurdles, from scientific complexities, to regulatory intricacies, finance, HR, and interactions with a wide range of stakeholders. In this dynamic landscape, the role of the Chair of the Board of Directors becomes pivotal. The Chair is well-positioned to empower and support first-time CEOs, but good synergy between the duo is paramount for success.

Managing the hype cycle of innovative medical device development

As a CDMO in the life science industry, Unitron has a focus on the development and manufacturing of “electronics-inside” medical devices and the associated regulatory trajectory. The journey from innovative ideas to successful products are often bumpy and filled with challenges. Having a good understanding of this process and managing it well will boost your chances of success.

V-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesity

VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a new spin-off company based on research at the VIB-UGent Center for Inflammation Research. With an initial seed financing round supported by V-Bio Ventures, Qbic and VIB, the spin-off company is entering the obesity space with an entirely novel therapeutic approach.

Obulytix is developing a revolutionary solution for antibiotic resistance

Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.

Azalea Vision announces first on-eye test of ALMA, its revolutionary smart contact lens

In a significant milestone, Azalea Vision, pioneering start-up on a mission to revolutionize the treatment of ocular disorders, announces the successful demonstration of ALMA Lens, the first functional prototype of the Azalea smart contact lens’ platform.